Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine
2024-06-25
疫苗紧急使用授权临床研究上市批准
Preview
来源: Pharmaceutical Technology
NVX-CoV2705 is a modified formulation of the original Covid-19 vaccine. Credit: benjamin poturak / Shutterstock.
Novavax has submitted a type II variation application with the European Medicines Agency (EMA) seeking approval for its updated JN.1 Covid-19 vaccineCovid-19 vaccine, NVX-CoV2705, for people aged 12 years and above.
The company’s filing for a variation of existing marketing authorisation aligns with guidance from the EMA and the World Health Organization to update vaccines to target the JN.1 lineage for autumn 2024.
According to nonclinical studies, the Novavax JN.1 Covid-19 vaccineCovid-19 vaccine elicited a broad neutralising response against JN.1 lineage viruses, including those with the F456L and R346T mutations and the FLiRT and FLuQE variants.
The vaccine also generates robust Th1-biased CD4+ T cell responses to JN.1 lineage variants. NVX-CoV2705 specifically targets the parent strain of the KP.2 and KP.3.2 lineages.
Novavax aims to make the vaccine available in unit-dose vials for distribution within the European Union on receipt of approval.
See Also:WHO warns of “harmful” fake Ozempic in circulation in Americas and Europe
Preview
来源: Pharmaceutical Technology
NNC-06500013 by Novo Nordisk for Type 2 Diabetes: Likelihood of Approval
Preview
来源: Pharmaceutical Technology
The company has also sought authorisation from the US Food and Drug Administration (FDA) and is in discussions with other global regulatory bodies for the approval of its JN.1 Covid-19 vaccineCovid-19 vaccine.
NVX-CoV2705 is a modified formulation of Novavax’s original Covid-19 vaccine, NVX-CoV2373, and is designed to target the JN.1 variant.
It utilises a protein-based technology to produce non-infectious copies of the SARS-CoV-2 spike protein, which primes the immune system to recognise the virus. The inclusion of Novavax’s Matrix-M adjuvant aims to enhance and extend the immune response.
The vaccine is provided as a ready-to-use liquid and can be stored at temperatures between 2° to 8°C, which allows for the use of existing vaccine supply chains and cold storage facilities.
“Our updated Covid-19 vaccine is active against current circulating strains, including KP.2 and KP.3.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。